Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096778 · ClinicalTrials.gov registry record · Phase 2
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by CellCentric.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT07096778: Recruiting Phase 2 study, sponsored by CellCentric.
NCT07096778 is a Phase 2 study that is actively recruiting participants, run by CellCentric. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07096778, a Phase 2 study, is actively recruiting participants, sponsored by CellCentric.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Inobrodib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 2 |
What NCT07096778 shows while recruiting
NCT07096778 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT07096778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07096778 about?
NCT07096778 is a clinical study titled "Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma". The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment wil...
What is the current status of trial NCT07096778?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-01-22. Estimated completion is 2029-12-01.
What interventions are being tested in trial NCT07096778?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Inobrodib (DRUG).
Who is sponsoring clinical trial NCT07096778?
This trial is sponsored by CellCentric, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07096778's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI